Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Athira Pharma Inc (ATHA)

Athira Pharma Inc (ATHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million GlobeNewswire - Thu Dec 18, 6:02AM CST

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...

ATHA : 7.21 (-3.99%)
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Nov 6, 3:05PM CST

Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable...

ATHA : 7.21 (-3.99%)
Athira Pharma Announces Reverse Stock Split GlobeNewswire - Thu Sep 11, 8:00AM CDT

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules...

ATHA : 7.21 (-3.99%)
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 GlobeNewswire - Thu Aug 14, 6:00AM CDT

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 7.21 (-3.99%)
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Aug 7, 3:05PM CDT

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 7.21 (-3.99%)
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit GlobeNewswire - Tue May 13, 10:00AM CDT

ATHA : 7.21 (-3.99%)
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates GlobeNewswire - Fri May 9, 3:05PM CDT

ATHA : 7.21 (-3.99%)
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates GlobeNewswire - Thu Feb 27, 3:05PM CST

ATHA : 7.21 (-3.99%)
Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium Quiver Quantitative, Inc. - Sat Dec 7, 2024

Athira Pharma presented preclinical data on ATH-1105's neuroprotective effects in ALS at an international symposium in Montreal.Quiver AI SummaryAthira Pharma, Inc., a clinical-stage biopharmaceutical...

ATHA : 7.21 (-3.99%)
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND GlobeNewswire - Fri Dec 6, 2024

ATHA : 7.21 (-3.99%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - Thu Dec 25, 6:30PM CST
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot